Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Capricor Therapeutics (CAPR) over the last 16 years, with Dec 2024 value amounting to $45.5 million.

  • Capricor Therapeutics' Shares Outstanding (Weighted Average) rose 40.50% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 40.50%. This contributed to the annual value of $45.5 million for FY2024, which is 47.66% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Shares Outstanding (Weighted Average) of $45.5 million as of FY2024, which was up 47.66% from $30.8 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Shares Outstanding (Weighted Average) registered a high of $45.5 million during FY2024, and its lowest value of $20.4 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $30.8 million (2023), whereas its average is $33.8 million.
  • Data for Capricor Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 381.55% (in 2020) over the last 5 years.
  • Over the past 5 years, Capricor Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $20.4 million in 2020, then climbed by 18.10% to $24.1 million in 2021, then climbed by 4.52% to $25.2 million in 2022, then climbed by 21.99% to $30.8 million in 2023, then surged by 47.66% to $45.5 million in 2024.